Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

stadapharm, gesellschaft mit beschränkter haftung (3364435) - etoricoxib - filmtablette - teil 1 - filmtablette; etoricoxib (30163) 90 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

stadapharm, gesellschaft mit beschränkter haftung (3364435) - etoricoxib - filmtablette - teil 1 - filmtablette; etoricoxib (30163) 60 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

stadapharm, gesellschaft mit beschränkter haftung (3364435) - etoricoxib - filmtablette - teil 1 - filmtablette; etoricoxib (30163) 30 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

acis arzneimittel gmbh (8087957) - natrium(methylprednisolon-21-succinat) - pulver und lösungsmittel zur herstellung einer injektions- bzw. infusionslösung - teil 1 - pulver zur herstellung einer injektions- /infusionslösung; natrium(methylprednisolon-21-succinat) (07524) 1325,92 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

1 a pharma gmbh (8013083) - ibuprofen - filmtablette - teil 1 - filmtablette; ibuprofen (05682) 600 milligramm

Den Europæiske Union - tysk - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastische mittel - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Den Europæiske Union - tysk - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptika, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Den Europæiske Union - tysk - EMA (European Medicines Agency)

eli lilly nederland b.v. - tirzepatide - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 und 5.

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mitsubishi tanabe pharma europe ltd. (8054691) - argatroban - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; argatroban (24492) 100 milligramm

Den Europæiske Union - tysk - EMA (European Medicines Agency)

pharmathen s.a. - ibandronsäure - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - medikamente zur behandlung von knochenerkrankungen - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. behandlung von tumorinduzierter hyperkalzämie mit oder ohne metastasen. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.